Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study [0.03%]
西班牙TRIP研究：恩曲他滨/富马酸替诺福韦酯与其它核苷类似物在西班牙50岁及以上初治患者中的安全性、有效性和持久性分析
José Ramón Blanco,Ana María Caro-Murillo,Manuel Angel Castaño et al.
José Ramón Blanco et al.
Objectives: Current antiretroviral guidelines state that being older than 50 to 55 years of age is an indication to start antiretroviral therapy (ART), regardless of CD4 status. However, no references to the preferred com...
Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor [0.03%]
GSK1265744的药代动力学、安全性和抗病毒活性研究：一种HIV整合酶链转移抑制剂
W Spreen,S Min,S L Ford et al.
W Spreen et al.
Background: GSK1265744 is an HIV integrase strand transfer inhibitor selected for clinical development. Objective: This first-time-in-h...
Clinical Trial
HIV clinical trials. 2013 Sep-Oct;14(5):192-203. DOI:10.1310/hct1405-192 2013
Long-term safety study of fosamprenavir-containing regimens in HIV-1-infected patients [0.03%]
一项关于福沙匹拉韦方案长期安全性的研究
Robin Wood,Joseph C Gathe,Naomi Givens et al.
Robin Wood et al.
Background: Safety and efficacy of the protease inhibitor fosamprenavir (FPV) ± ritonavir (r) was evaluated in 3 pivotal 48-week phase III studies. A follow-on study provides long-term data on FPV-based regimens. ...
Clinical Trial
HIV clinical trials. 2013 Sep-Oct;14(5):183-91. DOI:10.1310/hct1405-183 2013
Immune response after a single dose of the 2010/11 trivalent, seasonal influenza vaccine in HIV-1-infected patients and healthy controls [0.03%]
HIV感染者和健康人单次接种2010/2011年三价季节性流感疫苗后的免疫反应
Markus Bickel,Christin Lassmann,Imke Wieters et al.
Markus Bickel et al.
Background: Immune response rates following influenza vaccination are often lower in HIV-infected individuals. Low vitamin D levels were correlated with weak immune response in cancer patients and are known to be lower in...
Controlled Clinical Trial
HIV clinical trials. 2013 Jul-Aug;14(4):175-81. DOI:10.1310/hct1404-175 2013
Pilot study of younger and older HIV-infected adults using traditional and novel functional assessments [0.03%]
采用传统和新颖的功能评估方法对HIV阳性年轻患者和老年患者的试点研究
Uriel Sandkovsky,Kevin R Robertson,Jane L Meza et al.
Uriel Sandkovsky et al.
Objectives: Emerging data suggest that HIV disease and its treatment affect the aging process. Accurate and reliable measures of functional status are needed to investigate this further. ...
Flow cytometry analysis with a new FITC-conjugated monoclonal antibody-3E12 for HLA-B*57:01 rapid screening in prevention of abacavir hypersensitivity in HIV-1-infected patients [0.03%]
一种新型FITC标记单克隆抗体3E12流式细胞分析法在HIV-1感染者中筛查HLA-B*57:01以预防阿巴卡韦过敏反应中的应用
C Rodríguez-Sáinz,L Valor,D C Hernández et al.
C Rodríguez-Sáinz et al.
Background: Rapid screening for the detection of HLA-B*57:01 in the prevention of abacavir hypersensitivity in HIV-1-infected patients is a hallmark for clinical services. ...
Baseline CD4+ T-cell counts predict HBV viral kinetics to adefovir treatment in lamivudine-resistant HBV-infected patients with or without HIV infection [0.03%]
基线CD4+T细胞计数可预测拉米夫定耐药的HBV感染患者(无论是否合并HIV)对阿德福韦治疗下的HBV病毒动力学反应
K J Cortez,M A Proschan,L Barrett et al.
K J Cortez et al.
Background: Coinfection with HIV and hepatitis B virus (HBV) substantially alters the course of HBV. Directly acting anti-HBV agents suppress HBV viral levels; however, the kinetics of HBV decline in mono- and coinfected ...
Randomized Controlled Trial
HIV clinical trials. 2013 Jul-Aug;14(4):149-59. DOI:10.1310/hct1404-149 2013
Randomized trial to evaluate cardiometabolic and endothelial function in patients with plasma HIV-1 RNA suppression switching to darunavir/ritonavir with or without nucleoside analogues [0.03%]
一项随机试验：评估使用达芦那韦/利托那韦（有或没有核苷类似物）治疗使血浆HIV-1RNA抑制的患者的心代谢和内皮功能的效果
G Guaraldi,S Zona,A Cossarizza et al.
G Guaraldi et al.
Background: We performed a study to evaluate change in cardiometabolic and endothelial function in HIV-infected patients switching to darunavir/ritonavir (DRV/r) monotherapy versus triple therapy. ...
Randomized Controlled Trial
HIV clinical trials. 2013 Jul-Aug;14(4):140-8. DOI:10.1310/hct1404-140 2013
Sustained virological response and baseline predictors in HIV-HCV coinfected patients retreated with pegylated interferon and ribavirin after failing a previous interferon-based therapy: systematic review and meta-analysis [0.03%]
直接抗病毒疗法前接受基于干扰素治疗的HIV-HCV合并感染患者再次治疗的持续病毒学应答及基线预测因素：系统综述和meta分析
Monica Basso,Saverio Giuseppe Parisi,Carlo Mengoli et al.
Monica Basso et al.
Background: Published data on retreatment with pegylated interferon and ribavirin of previously failing HIV-HCV coinfected patients are sparse and limited to observational study. We aimed to evaluate efficacy and pretreat...
Long-term HIV-1 virologic control in patients on a dual NRTI regimen [0.03%]
二重核苷类逆转录酶抑制剂方案对人类免疫缺陷病毒长期病毒学控制的影响
Thierry Prazuck,David Zucman,Véronique Avettand-Fènoël et al.
Thierry Prazuck et al.
Background: Since the release of protease inhibitors, only 2 randomized trials in the late 1990s have re-assessed the potency of dual nucleoside reverse transcriptase inhibitor (NRTI) combination (2N) as a maintenance str...